Dr. Reddy's Laboratories (RDY) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TG Therapeutics (TGTX) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 49.2% versus a loss of 12.8%. Over five years, TGTX leads with a +60.1% price change compared with -7.6% for RDY. Dr. Reddy's Laboratories is the larger company by market cap ($10.42 billion vs $8.40 billion), about 1.2 times the size, while TG Therapeutics is growing revenue faster (+87.3% vs +13.8%).
On valuation, Dr. Reddy's Laboratories trades at a lower forward P/E (19.5x vs 20.3x for TG Therapeutics). Dr. Reddy's Laboratories pays a dividend yielding 63.97%, while TG Therapeutics does not currently pay one. TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus 17.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RDY | TGTX |
|---|---|---|
| Share price | $12.51 | $54.85 |
| Market cap | $10.42B | $8.40B |
| 1-day change | +2.50% | +2.83% |
| YTD return | -13.11% | +78.93% |
| 1-year return | -12.79% | +49.20% |
| 5-year return | -7.59% | +60.13% |
| P/E ratio (TTM) | 28.42 | 19.95 |
| Forward P/E | 19.49 | 20.25 |
| EPS (TTM) | $0.44 | $2.75 |
| Dividend yield | 63.97% | 0.00% |
| Annual dividend | $8.00 | $0.00 |
| Revenue (latest FY) | $3.81B | $616.29M |
| Revenue growth (YoY) | +13.76% | +87.32% |
| Net income (latest FY) | $663.00M | $447.18M |
| Gross margin | 58.51% | 83.66% |
| Operating margin | 22.09% | 20.01% |
| Net margin | 17.40% | 72.56% |
| 52-week high | $15.67 | $59.30 |
| 52-week low | $11.36 | $26.76 |
| Distance from 52-week high | -20.20% | -7.50% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +5.72% | +27.09% |
| Average volume | 2.87M | 2.01M |
| Shares outstanding | 832.99M | 153.08M |
| Employees | 27,527 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TGTX has outperformed RDY by 62.0 percentage points over the past year.
- Dr. Reddy's Laboratories trades at a higher earnings multiple (28.4x vs 19.9x trailing P/E).
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (63.97% vs 0.00%).
- TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus 17.4 cents for Dr. Reddy's Laboratories.
- TG Therapeutics grew revenue faster in its latest fiscal year (+87.32% vs +13.76%).
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
RDY vs TGTX FAQ
Which is bigger, Dr. Reddy's Laboratories or TG Therapeutics?
Dr. Reddy's Laboratories (RDY) is larger, with a market capitalization of $10.42B compared with $8.40B for TG Therapeutics (TGTX).
Which stock has performed better over the past year, RDY or TGTX?
TGTX returned +49.20% over the past 12 months, compared with -12.79% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, RDY or TGTX?
TGTX has the lower trailing P/E at 19.9, versus 28.4 for RDY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Dr. Reddy's Laboratories or TG Therapeutics?
Dr. Reddy's Laboratories pays a dividend yielding 63.97%, while TG Therapeutics does not currently pay a regular dividend.
Are Dr. Reddy's Laboratories and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.